{"id":19169,"date":"2025-06-16T14:06:04","date_gmt":"2025-06-16T13:06:04","guid":{"rendered":"https:\/\/absolwent.umw.edu.pl\/?p=19169"},"modified":"2025-06-16T14:08:25","modified_gmt":"2025-06-16T13:08:25","slug":"graduates-received-the-wroclaw-magnolia","status":"publish","type":"post","link":"https:\/\/absolwent.umw.edu.pl\/en\/graduates-received-the-wroclaw-magnolia\/","title":{"rendered":"Graduates received the &#8220;Wroc\u0142aw Magnolia&#8221;"},"content":{"rendered":"<p><strong><span>The master&#8217;s thesis on improving the effectiveness of chronic lymphocytic leukemia (CLL) treatment with ibrutinib was awarded in the XXII edition of the &#8220;Wroc\u0142awska Magnolia&#8221; competition. Its author is \u0141ukasz Martowski, M.Pharm., a graduate of the Wroclaw Medical University.<\/span><\/strong><\/p>\n<p><em><span>Chronic Lymphocytic Leukemia<\/span><\/em><span>\u00a0(\u00a0CLL) is the most common blood cancer among Europeans. It affects men twice as often as women and usually occurs in patients over the age of 70.\u00a0<\/span><\/p>\n<p><span>Various drugs have been used in the treatment of CLL, but visible progress in therapy was only brought about by the discovery of TKI drugs (tyrosine kinase inhibitors), which inhibit the growth and spread of cancer cells. One of them is a drug containing ibrutinib (IBR), introduced in 2013.<\/span><\/p>\n<p><span>\u2013 However, treating chronic lymphocytic leukemia with ibrutinib in crystalline form is associated with high costs, the need for patients to take high doses and side effects \u2013 explains \u0141ukasz Martowski. \u2013 Therefore, one of the most important tasks currently facing scientists is to improve the selectivity of TKI drugs, reduce their toxicity and obtain better penetrating molecules.\u00a0<\/span><\/p>\n<p><span>The experimental research work of \u0141ukasz Martowski entitled &#8220;Physicochemical studies of amorphous solid dispersions of ibrutinib with a hydrophilic polymer&#8221;, supervised by Dr. Igor Mucha from the Department of Chemical Sciences, Faculty of Pharmacy, WMU, describes the possibilities of physical modification of ibrutinib using alternative amorphization methods.\u00a0<\/span><\/p>\n<p><span>\u2013 Amorphization can improve the bioavailability of the drug by increasing its solubility, which will accelerate and improve its action and increase the effectiveness of treatment \u2013 \u200b\u200badds the author of the paper.<\/span><\/p>\n<p><span>Implementing the solution could improve the prognosis for CLL patients, reduce the costs of drug production, and also raise the profile of Wroc\u0142aw as a research center and increase the involvement of local industry in the development of modern technologies.<\/span><\/p>\n<p><span>***<\/span><\/p>\n<p><span>&#8220;Wroc\u0142awska Magnolia&#8221; is a competition organized by the Wroc\u0142aw Academic Center (WAC). It is aimed at university graduates who take up topics related to improving the quality of life of city residents (e.g. protection of health and life or the natural environment) in their diploma theses, and the solutions they propose can be implemented.<\/span><\/p>\n<p><span>The awards ceremony was attended by dr hab. Piotr \u015awi\u0105tek, prof. WMU, vice-dean of the Faculty of Pharmacy for the pharmacy major, university coordinator of the &#8220;Wroc\u0142awska Magnolia&#8221; competition, who received a letter of congratulations and thanks from the mayor of Wroc\u0142aw Jacek Sutryk, and supervisor dr Igor Mucha, who received the distinction.<\/span><\/p>\n<p><em><span>Photo: Marek Ksi\u0119\u017carek<\/span><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The master&#8217;s thesis on improving the effectiveness of chronic lymphocytic leukemia (CLL) treatment with ibrutinib<\/p>\n","protected":false},"author":203,"featured_media":19166,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[510],"tags":[],"class_list":["post-19169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","has-featured"],"acf":[],"_links":{"self":[{"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/posts\/19169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/users\/203"}],"replies":[{"embeddable":true,"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/comments?post=19169"}],"version-history":[{"count":2,"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/posts\/19169\/revisions"}],"predecessor-version":[{"id":19171,"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/posts\/19169\/revisions\/19171"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/media\/19166"}],"wp:attachment":[{"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/media?parent=19169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/categories?post=19169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/absolwent.umw.edu.pl\/en\/wp-json\/wp\/v2\/tags?post=19169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}